These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 21219844)
21. Psychiatric disorders and depression in multiple sclerosis outpatients: impact of disability and interferon beta therapy. Galeazzi GM; Ferrari S; Giaroli G; Mackinnon A; Merelli E; Motti L; Rigatelli M Neurol Sci; 2005 Oct; 26(4):255-62. PubMed ID: 16193252 [TBL] [Abstract][Full Text] [Related]
22. Retinopathy during interferon-β treatment for multiple sclerosis: case report and review of the literature. Gaetani L; Menduno PS; Cometa F; Di Gregorio M; Sarchielli P; Cagini C; Calabresi P; Di Filippo M J Neurol; 2016 Mar; 263(3):422-7. PubMed ID: 26292794 [TBL] [Abstract][Full Text] [Related]
24. What is the best approach to treating interferon-induced depression in people with multiple sclerosis? Patten SB J Psychiatry Neurosci; 2001 Jan; 26(1):66. PubMed ID: 11212597 [No Abstract] [Full Text] [Related]
25. Combination therapy with interferon-beta and glatiramer acetate in multiple sclerosis. Ytterberg C; Johansson S; Andersson M; Olsson D; Link H; Holmqvist LW; von Koch L Acta Neurol Scand; 2007 Aug; 116(2):96-9. PubMed ID: 17661794 [TBL] [Abstract][Full Text] [Related]
26. Pharmacological management of depression in patients with multiple sclerosis. Carta MG; Paribello P; Anastasia A; De Berardis D; Nardi AE; Fornaro M Expert Opin Pharmacother; 2018 Oct; 19(14):1533-1540. PubMed ID: 30207800 [TBL] [Abstract][Full Text] [Related]
27. Depression in children and adolescents. Son SE; Kirchner JT Am Fam Physician; 2000 Nov; 62(10):2297-308, 2311-2. PubMed ID: 11126856 [TBL] [Abstract][Full Text] [Related]
28. Interferon beta, birth weight and pregnancy in multiple sclerosis. Hellwig K; Agne H; Gold R J Neurol; 2009 May; 256(5):830-1. PubMed ID: 19240959 [No Abstract] [Full Text] [Related]
29. Guidelines for treating depression using non-selective serotonin reuptake inhibitors. Withersty DJ; Vanin JR W V Med J; 1999; 95(1):20-3. PubMed ID: 9949692 [TBL] [Abstract][Full Text] [Related]
30. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Kappos L; Freedman MS; Polman CH; Edan G; Hartung HP; Miller DH; Montalbán X; Barkhof F; Radü EW; Bauer L; Dahms S; Lanius V; Pohl C; Sandbrink R; Lancet; 2007 Aug; 370(9585):389-97. PubMed ID: 17679016 [TBL] [Abstract][Full Text] [Related]
31. The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis. Patten SB; Francis G; Metz LM; Lopez-Bresnahan M; Chang P; Curtin F Mult Scler; 2005 Apr; 11(2):175-81. PubMed ID: 15794391 [TBL] [Abstract][Full Text] [Related]
32. Soluble BAFF Level Is Not Correlated to Mycobacterium avium Subspecies Paratuberculosis Antibodies and Increases After Interferon-β Therapy in Multiple Sclerosis Patients. Mameli G; Cossu D; Caggiu E; Arru G; Niegowska M; Cocco E; Frau J; Marrosu MG; Sechi LA J Mol Neurosci; 2016 Sep; 60(1):91-3. PubMed ID: 27370541 [TBL] [Abstract][Full Text] [Related]
33. Antidepressant monotherapy for bipolar type II major depression. Amsterdam JD; Brunswick DJ Bipolar Disord; 2003 Dec; 5(6):388-95. PubMed ID: 14636362 [TBL] [Abstract][Full Text] [Related]
34. Long-term emotional state of multiple sclerosis patients treated with interferon beta. Porcel J; Río J; Sánchez-Betancourt A; Arévalo MJ; Tintoré M; Téllez N; Borràs C; Nos C; Montalbán X Mult Scler; 2006 Dec; 12(6):802-7. PubMed ID: 17263010 [TBL] [Abstract][Full Text] [Related]
35. [Logistics and description of treatment technology (the protocol for using disease modifying drugs--DMD)]. Federal service on surveillance in healthcare and social development (Roszdravnadzor) Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):93-8. PubMed ID: 21916163 [No Abstract] [Full Text] [Related]
36. Suicide attempts in multiple sclerosis. Stenager EN; Jensen B; Stenager M; Stenager K; Stenager E Mult Scler; 2011 Oct; 17(10):1265-8. PubMed ID: 21511689 [TBL] [Abstract][Full Text] [Related]
38. Intramuscular interferon-beta-1a: in patients at high risk of developing clinically definite multiple sclerosis. Siddiqui MA; Wellington K CNS Drugs; 2005; 19(1):55-61; discussion 63-4. PubMed ID: 15651905 [TBL] [Abstract][Full Text] [Related]
39. Pulmonary arterial hypertension associated with interferon-beta treatment for multiple sclerosis. Case report and literature review. Demerouti E; Karyofyllis P; Athanassopoulos G; Karatasakis G; Tsiapras D; Manginas A; Voudris V Mult Scler Relat Disord; 2019 Feb; 28():273-275. PubMed ID: 30639829 [TBL] [Abstract][Full Text] [Related]
40. Interferon beta-1 a and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial. Patten SB; Metz LM Mult Scler; 2001 Aug; 7(4):243-8. PubMed ID: 11548984 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]